Ultra-Fast CAR-T, Affordable and Accessible Cell Therapy for All Transforming access to curative cell therapy through next-generation, less than 1 day CAR-T manufacturing.

About Us

Our Mission:

To make life-saving cell therapies accessible to every patient, everywhere. Kure Cells is re-engineering the CAR-T manufacturing process to remove the barriers of cost, time, and complexity that have kept this transformative therapy out of reach for most of the world.

Our Story:

Founded by clinicians and scientists, Kure Cells brings together innovation from the lab bench, the clinic, and the bioprocess engineering floor. Our proprietary Ultra-Fast (UF) CAR-T platform cuts manufacturing time from weeks to less than 24 hours—while preserving T-cell stemness and therapeutic potency. Headquartered in Ohio, Kure is expanding global operations with programs in the U.S., Middle East, Europe, India, and Latin America.

Technology

The Ultra-Fast CAR-T Platform Kure’s breakthrough platform delivers CAR-T products that are faster to make, more potent, and more scalable. Key Advantages:

Speed: Manufacturing completed within 24 hours.

Scalability: Semi-automated, closed-system process adaptable to regional GMP sites.

Quality: Enrichment of naïve/stem-like T cells enhances persistence and safety.

Vector Innovation: Utilizes proprietary lentiviral backbones and enhancer plasmids increase transduction efficiency while lowering cost.

Safety: Reduced cytokine release syndrome (CRS) and neurotoxicity observed clinically.

Broader Applications: The same platform is being adapted for solid tumors, autoimmune diseases.

Response rate: 88% complete remission in phase 1 for UF-kure19

Cost: Dramatic cost reduction

UF-Kure19

UF-Kure-BCMA

Our Work

Pipeline

Pipeline

UF-KURE19

Target / Indication

CD19 / Relapsed or Refractory NHL

Stage

Completed Phase 1 (US); Phase 2 planned (International)

Highlights

88% CR rate with high durability; excellent safety (low CRS/neurotoxicity)

Target / Indication

BCMA / Relapsed or Refractory Multiple Myeloma

Stage

IND Cleared; Phase 1 pending

Highlights

Direct-from-blood manufacturing

UF-KURE-BCMA

Multiple solid tumor CARs

Target / Indication

Pan-cancer Targets for solid tumors

Stage

Pre-clinical

Highlights

First-in-class CAR-T against novel targets

What's New

News & Stories

Internships

Et harum quidem rerum facilis est et expedita mea voluptas fuga quod mea.

read more
;

Careers

Et harum quidem rerum facilis est et expedita mea voluptas fuga quod mea.

view open positions

Investitors

Et harum quidem rerum facilis est et expedita mea voluptas fuga quod mea.

grow with us

Partner With Us

Our strategic partner CellServe supports clinical trial operations and global study execution.

Kure Cells is actively engaging with:

Investors interested in scalable, next-generation immunotherapy platforms.

Clinical centers seeking rapid-manufacturing CAR-T trials.

Strategic partners in manufacturing and commercialization.

Contact

Email: inquiries@kure.ai